Showing 17,061 - 17,080 results of 44,806 for search '(( 50 ((ms decrease) OR (a decrease)) ) OR ( 5 ((ng decrease) OR (mean decrease)) ))', query time: 1.30s Refine Results
  1. 17061
  2. 17062
  3. 17063
  4. 17064
  5. 17065

    A. We randomly selected 20 mutually exclusive groups of protein complexes that contained exactly five subunits; we mapped the corresponding gene pairs to SINaTRA scores, and plotte... by Alexandra Jacunski (5665486)

    Published 2015
    “…We compared the fraction of gene pairs with products in the same vs. different complexes for three SINaTRA cutoffs (0.95, 0.80, 0.50) as well as for all gene pairs. A SINaTRA cutoff of 0.95 has approximately half of its pairs associated with the same complex; however, a decrease in the cutoff shifts this balance. …”
  6. 17066

    Data_Sheet_1_Efficacy and safety of single-dose ivermectin in mild-to-moderate COVID-19: the double-blind, randomized, placebo-controlled CORVETTE-01 trial.docx by Tatsuhiko Wada (14391781)

    Published 2023
    “…</p>Results<p>Overall, 112 and 109 patients were randomized to ivermectin and placebo, respectively; 106 patients from each group were included in the full analysis set (male [%], mean age: 68.9%, 47.9 years [ivermectin]; 62.3%, 47.5 years [placebo]). …”
  7. 17067

    Data_Sheet_1_Efficacy and safety of single-dose ivermectin in mild-to-moderate COVID-19: the double-blind, randomized, placebo-controlled CORVETTE-01 trial.docx by Tatsuhiko Wada (14391781)

    Published 2023
    “…</p>Results<p>Overall, 112 and 109 patients were randomized to ivermectin and placebo, respectively; 106 patients from each group were included in the full analysis set (male [%], mean age: 68.9%, 47.9 years [ivermectin]; 62.3%, 47.5 years [placebo]). …”
  8. 17068

    Data_Sheet_1_Efficacy and safety of single-dose ivermectin in mild-to-moderate COVID-19: the double-blind, randomized, placebo-controlled CORVETTE-01 trial.docx by Tatsuhiko Wada (14391781)

    Published 2023
    “…</p>Results<p>Overall, 112 and 109 patients were randomized to ivermectin and placebo, respectively; 106 patients from each group were included in the full analysis set (male [%], mean age: 68.9%, 47.9 years [ivermectin]; 62.3%, 47.5 years [placebo]). …”
  9. 17069
  10. 17070
  11. 17071

    Fluorescence time-lapse imaging of a single GPR3-HT-expressing CGN. by Tatsuhiro Miyagi (847543)

    Published 2016
    “…<p>(A-B) The CGNs were transfected with the pGPR3-HT expression vector and were plated onto 0.03% PEI-coated plates. …”
  12. 17072

    (A) Effect of calcium chelators and K channel antagonist, ChTX on fEPSP during OGD. by Shirin Jalini (2551054)

    Published 2016
    “…<b>(</b>B) Effect of calcium chelators, and BK channel antagonist on recovery of fEPSP after OGD. BAPTA-AM (1 μM) decreases recovery time from 2 min (n = 7), 4 min (n = 6) and 6 min (n = 3) of <i>in vitro</i> OGD compared to control (n = 7, 5, 5, respectively). …”
  13. 17073
  14. 17074
  15. 17075
  16. 17076

    Nick closing activity of <i>w</i>Bm-LigA and biochemical characterization. by Nidhi Shrivastava (315987)

    Published 2013
    “…<p>(A) Effect of enzyme substrate ratio on nick closing activity. …”
  17. 17077
  18. 17078
  19. 17079
  20. 17080